ArticleTurkish journal of chemistry2022
The investigation of parameters affecting Ibrutinib release from chitosan/tripolyphosphate/carbon nanofiber composite microspheres.
Article in Turkish journal of chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An overview of advanced nanocarrier systems for Ibrutinib delivery: overcoming pharmacokinetic barriers and enabling targeted cancer therapy.International journal of pharmaceutics: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study described the performance of carbon nanofiber modified chitosan (CNF@CS) composite microspheres for the controlled release of the Ibrutinib (IBR) drug. The surface morphology, particle sizes, and functional group contents of the microspheres were characterized by attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR), scanning electron, and optical microscopy measurements. The obtained data demonstrated that the addition of CNF to the microsphere increased the encapsulation efficiency of the IBR while allowing the controlled and gradual release of the drug. In terms of the encapsulation efficiency and drug release rate, IBR@CS/TPP/CNF microspheres, achieving drug encapsulation efficiency of 83.09%, have the most suitable formulation according to the comparative studies. Furthermore, according to Korsmeyer-Peppas kinetic model, IBR release mechanism was anomalous diffusion (swelling-controlled behavior and diffusion.) because the IBR release profile was completed in 78 h under optimized conditions. Therefore, the development of CNF based chitosan microsphere is a promising approach to assure appropriate dosage, safety, and improving drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.